When Eli Lilly announced plans to build a $6.5 billion manufacturing facility in Houston, Texas, it made headlines far beyond the pharmaceutical sector. The facility will produce active ingredients for orforglipron, Lilly’s experimental oral GLP-1 therapy for obesity and type 2 diabetes—an innovation with blockbuster potential in a market already reshaped by injectable weight-loss drugs.
But the announcement is more than a story of a single plant. It’s a case study in how corporate strategy, market opportunity, and shifting political winds converge to shape billion-dollar decisions.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
